Member Info for Chefmassive

So the Nasdaq bounced strongly off $0.23 yesterday now sitting at $0.32, last trading day before the reverse split, what will happen today? Expecting fireworks over the next couple of trading days

Only one trading day left before the reverse split on the Nasdaq on Monday, they have tried hard to shake off investors this week, I think we may see a rise from here, nearly took off today on LSE.

We are still worth 11p on the Nasdaq at the moment, I’m happy to be holding over here rather than on the Nasdaq at the moment, definitely being walked down over there!

Well they have to bring the prices closer together before the 08/04/19, let’s hope they don’t just drop the Nasdaq all the way, but they raise the LSE shares at some stage.

Before the reverse split on the Nasdaq, currently we have an exchange price of approximately £0.12 so either we have a long way to rise or the Nasdaq has a long way to fall, anywhere between £0.635 and £0.12 is a good start for me

Google “ Midatech CFO interview” its a great watch my link was removed as it’s not allowed on LSE. Shows how much the Spanish government are backing Midatech, makes me feel very comfortable holding here, especially at these levels.

Access to 48000 Hospitals in China, is alone quite astounding, this relationship should prove to be massive for Midatech. “The collaboration provides Midatech with a key strategic partnership in China and South East Asia, access to the significant Chinese market, substantial investment and funds for Midatech's current key programs, as well as additional CMS funded opportunities for the Company's technology platforms Q-Sphera, MidaSolve, and MidaCore”. Additional CMS funded opportunities, there’s another hidden gem in the 26th Feb RNS

CMS (China Medical System) China Medical System Holdings Limited (HKG: 0867), is a well-established, innovation-driven specialty pharma with a focus on sales and marketing in China. CMS has established the diversified product introduction strategies to constantly provide competitive products and services to fulfil the unmet medical needs of the China market, as well as to sustain the momentum for its future development. CMS has a fully-covered nationwide promotional network, mainly focusing on academic promotion. As at 30 June 2018, CMS covered over 48,000 hospitals and medical institutions across China.

I bet there will be a lot of interest built up over the weekend as the news gets out. https://www.proactiveinvestors.co.uk/companies/news/217500/midatech-pharma-shares-soar-as-it-receives-66mln-from-spanish-government-217500.html

Great price to get in here early today, glad I topped up last week

MTD201 is a treatment for acromegaly and neuroendocrine (NET) tumours such as carcinoid cancer, and is based on the Company's novel polymer microsphere technology, Q-Sphera™ for sustained release delivery. The leading product currently in this $2 billion market is Novartis' Sandostatin® LAR® ("SLAR"). Data from Midatech's recent Phase I exploratory study demonstrated that MTD201 produces a safe and effective sustained delivery profile of Octreotide, with further advantageous characteristics which strongly supports the continued development of a long-acting octreotide product alternative to SLAR for treatment of these diseases. CEO Craig Cook commented 'The Reindus loan is a real boost to our commercial manufacturing scale up scheduled over the next 18 - 24 months in Bilbao and, together with other alternative options under consideration by the Board such as strategic manufacturing partnerships, can provide all our manufacturing needs in the medium to long term. For our lead program MTD201, completion of the commercial manufacturing is required prior to submitting for marketing authorization in the US and EU, and the Reindus loan allows us to plan and move ahead with more confidence.'

Midatech today announces that on 28th March 2019, the Spanish government notified the Company that it has provisionally approved the Company's Reindustrialisation ("Reindus") loan application relating to Midatech's plans for commercial scale-up of its key MTD201 Q-Octreotide development product. The loan amount conditionally approved under Reindus is €6.6m ("Loan"), which brings the total public financing available for this project to €8.5m, including previous amounts recently approved by the Basque regional government. The total manufacturing cost of the project is being finalised and is currently estimated at approximately €16m. This quantum remains subject to finalisation of a number of variables. Provision of the Loan is subject to Midatech providing a €2.6m guarantee ("Guarantee"), which Reindus requires as part of the terms of the Loan to be paid within 15 days of formal request by Reindus, which is expected within the next month. The Guarantee, and any other potential costs not covered by the approved funding such as personnel costs, is likely to be funded by bank finance and other Basque funding institutions. The Loan will accrue interest at a rate of 1.6%. Repayments commence 3 years after drawdown, and the repayment period thereafter is 10 years.

Spanish government loan approval RNS

Still holding strong on the Nasdaq compared to our price we have a nice gap to fill. Broker prices are in another galaxy at the moment but it shows how this could soon fly, results due out in April Panmure Gordon price target £2.97 N +1 Singer £1.40 Percentage of shares in sticky hands is now much greater making the free float more appealing to investors. More news to pop anytime now. Always a risk buying into pharma but the upside is looking better by the day.

Nice to see the Nasdaq held up its price yesterday, hoping for the rise to continue today and upto results next month. 10 x $0.40 = 4 divide by 20 = 0.2 $0.2 converted to £0.15 If this share stays strong on the Nasdaq leading till 8th April, then we are looking long and strong over here, in my view the gap is to big for the U.K. shares not to go up. Only my opinion fingers crossed for some short term growth here.

10 x $0.37 = 3.7 decide by 20 = 0.185 $0.185 convert to £0.14

Boom

Looks interesting what the next move is going to be here, two massive trades yesterday at identical prices, 6000000 shares each trade, annual results due next month, big deal with China pipeline, possible Q1 results due. T’s crossed and I’s dotted, are we looking at great results or a possible buy out, who knows but I do feel we are on the verge of greater things.

All buys today not one sell, Nasdaq seems to be ready for another rise, let’s hope the sellers are out and the rise can continue.

http://www.investorsobserver.com/memberships/stocks/stock-report/?utm_medium=email&utm_source=190309+stock+report+confirmation&utm_campaign=PR+Stock+Confirmation&utm_content=Confirmation+Link&key=gYE34cNIQWY2KHwFoqpt&symbol=MTP&pr=022820190&subid=3C7498FB-C626-4CF0-AA57-763BEF0635E4